SARS-CoV-2 Booster Vaccination for Participants in “HIV Cure”–Related Clinical Trials

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to present challenges for HIV cure-related research studies, particularly those that involve immunomodulatory therapy and/or the interruption of HIV treatment. People living with HIV (PLWH) are likely to be at higher risk for adverse outcomes following SARS-CoV-2 infection, and this risk is more pronounced in those with lower CD4+ T cell counts or elevated plasma HIV RNA levels. It is the obligation of those directing research studies involving PLWH to appropriately advise study volunteers and attempt to mitigate risks related to potential SARS-CoV-2 exposure and infection.